Loading…
KZIA
Kazia Therapeutics Ltd
NASDAQ· Healthcare· Biotechnology· CUSIP 48669G303
$7.25-2.03%Price as of Oct 17, 12:06 UTC · updated once a day, after the close
At a glance
Kazia Therapeutics Ltd (KZIA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Sydney, Australia and has 6 employees. The company is worth $82.85M. Revenue was A$42K in fiscal 2025, down 98.2% from the year before. It reported a net loss of A$20.7M. The share price is 58.3% below its 52-week high of $17.40. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $2.3M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $82.85M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.6x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$6.85
- ROE
- -106.90%
- Profit margin
- 0.00%
- Revenue growth
- +312.40%
- Beta
- 2.27
- 52-week high
- $17.40
- 52-week low
- $4.86
History
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in AUD, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.6% over 5Y.
today you would have $13.39▼ -98.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $6.89 | $8.85 | $22.00 | $30.50 | |
| EPS | -A$18.90 | — | -A$56.15 | -A$93.05 | |
| Profit margin | — | -49290.48% | -1160.23% | — | — |
| ROE | — | — | — | -169.83% | -136.88% |
This company reports in AUD, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by AUD, so they are not shown; EPS is in AUD. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| AARDAardvark Therapeutics, Inc. | $3.78 | — | 1.1x | 0.00% | -66.02% | $82.72M |
| PDSBPDS Biotechnology Corp | $1.13 | — | — | 0.00% | -543.97% | $81.9M |
| SERASERA Prognostics Inc | $2.06 | — | 1.4x | 0.00% | -45.03% | $81.27M |
| CTORCitius Oncology Inc | $0.77 |
About the company
- 6
- Sydney, Australia